<DOC>
	<DOCNO>NCT02398929</DOCNO>
	<brief_summary>This open-label , placebo run-in study investigate genetic biomedical predictor blood pressure response bisoprolol . After informed consent obtain , subject withdraw previous antihypertensive therapy give placebo least 2 week . Compliance assess use pill counting , subject compliance le 80 % placebo run-in period exclude study . Bisoprolol 2.5 mg give daily 6 week . At baseline 6 week bisoprolol 2.5 mg clinic sit blood pressure , 24-hour ambulatory blood pressure ( patient willing ) , clinical characteristic biochemical profile measure . Central aortic blood pressure measure A-PULSE device baseline 6 week treatment . After complete 6 week treatment bisoprolol 2.5 mg daily , patient continue treatment bisoprolol total 24 week unless adverse event require discontinuation bisoprolol .</brief_summary>
	<brief_title>BRAVE Study With Uncontrolled Essential Hypertension ( BRAVE Study )</brief_title>
	<detailed_description>Patients uncontrolled essential hypertension age 18-79 year antihypertensive treatment sit clinic systolic blood pressure 140-169 mmHg and/or sit clinic diastolic blood pressure 90-109 mmHg , patient diabetes mellitus chronic kidney disease sit clinic systolic blood pressure 130-169 mmHg / sit clinic diastolic blood pressure 80-109 mmHg heart rate &gt; 70 baseline ( start bisoprolol treatment ) enrol . Patients antihypertensive treatment experience side effect whose blood pressure may well control also enter continue stable dose calcium channel blocker , either amlodipine nifedipine retard throughout study . Patients treat bisoprolol 2.5mg daily total 26 week . The primary endpoint influence common genetic polymorphism clinic sit blood pressure ambulatory blood pressure ( ABP ) response bisoprolol 2.5 mg 6 week treatment .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Bisoprolol</mesh_term>
	<criteria>Patients essential hypertension For uncomplicated hypertensive patient antihypertensive treatment , sit clinic systolic blood pressure 140169 mmHg / sit clinic diastolic blood pressure 90109 mmHg . For patient diabetes mellitus chronic kidney disease , sit clinic systolic blood pressure 130169 mmHg / sit clinic diastolic blood pressure 80109 mmHg . Patient heart rate &gt; 70 b/min baseline ( start bisoprolol treatment ) Secondary Hypertension Pregnant lactate woman woman childbearing potential use adequate method contraception agree maintain sexual abstinence throughout study ; Unstable angina , history myocardial infarction , stroke coronary heart disease ( coronary bypass angioplasty ) previous 3 month ; Heart failure ( New York Heart Association [ NYHA ] IIIIV ) ; Haemodynamically relevant aortic mitral valve disease ; Obstructive hypertensive cardiomyopathy ; Symptomatic bradycardia , second third degree atrioventricular ( AV ) block , sick sinus syndrome , sinoatrial block , heart rate &lt; 70 b/min baseline ( start bisoprolol treatment ) ; Primary hyperaldosteronism ; Renal artery stenosis ; Impairment hepatic renal function define liver function value ALT ≥1.5fold upper normal limit serum creatinine &gt; 150 µmol/L upon investigator decision ; History intolerance betablockers drug class use study . Patients know contraindication betablockers , e.g . bradycardia , asthma , severe peripheral vascular disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>